HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

INNOGEN-B

3.940

+0.1052.74%

Volume:19.16M

Turnover:73.34M

Market Cap:1.80B

PE:-4.27

High:3.970

Open:3.785

Low:3.630

Close:3.835

52wk High:48.360

52wk Low:3.435

Shares:457.00M

HK Float Shares:420.29M

Volume Ratio:1.14

T/O Rate:4.56%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.923

ROE:-41.16%

ROA:-20.15%

PB:1.64

PE(LYR):-4.27

PS:10.05

Loading ...

Overview Company News Filings

Innogen says Phase IIb trial shows efsubaglutide alfa cuts weight up to 10.58% in adults with obesity

Stock Track | INNOGEN-B Plummets 6.52% Intraday as Cornerstone Investor Lock-ups Expire

Hong Kong Stocks Midday Recap: Hang Seng Index Dips 0.87%, Robotics Sector Surges Against Market Trend

Stock Track | INNOGEN-B Plummets 5.46% Intraday as Lock-Up Period Expires and Financial Losses Widen

INNOGEN-B Shares Extend Losses as Lock-Up Period Nears End

INNOGEN-B Shares Plunge Over 9% Following Previous Day's Surge, Lock-Up Period for Cornerstone Investors Nears End

INNOGEN-B Shares Surge Over 43% in Morning Trading; Phase III Weight Loss Data for Suba Anticipated by End-2026

INNOGEN-B Shares Hit Record Low as Lock-Up Expiry Nears

Innogen Pharmaceutical Reports No Share Capital Changes in April 2026; Public Float Remains Compliant

Bulletin Express

英诺加医药2025年首度实现收入破1.31509亿元，推进糖尿病及代谢病产品全球布局

Bulletin Express

Guangzhou Innogen Pharma publishes 2025 annual report

Domestic Long-Acting GLP-1 Drug Tops 100 Million Yuan in First-Year Sales but Faces Deepening Losses

INNOGEN-B (02591): 2025 Losses Nearly Double Amid Strategic Transition, Share Price Plummets Over 70%

INNOGEN-B Shares Climb Over 3% in Morning Session as Esupaglutide Alpha Added to Qilu Insurance List

Innogen Pharmaceutical's 2025 Loss Widens

MT Newswires Live

Stock Track | INNOGEN-B Plummets 5.79% Intraday as FY2025 Loss Widens 95.4% on Surging R&D and Commercial Expenses

BRIEF-Guangzhou Innogen Pharmaceutical Posts FY Revenue Rmb131.5 Million

INNOGEN-B Reports Widened Net Loss of 341 Million Yuan for Fiscal Year 2025

Innogen Pharmaceutical posts 2025 maiden revenue of RMB131.51 million; net loss widens on surging R&D and commercial spend

Bulletin Express

Guangzhou Innogen Pharmaceutical - Plans to Enter the Latin America Market

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/02591/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02591","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","market":"HK","secType":"STK","nameCN":"INNOGEN-B","latestPrice":3.94,"timestamp":1789027724005,"preClose":3.835,"halted":0,"volume":19157931,"delay":0,"changeRate":0.02737940026075619,"floatShares":420285370,"shares":457000000,"eps":-0.9229550871910676,"marketStatus":"Closed","change":0.105,"latestTime":"09-10 16:08:44","open":3.785,"high":3.97,"low":3.63,"amount":73338352,"amplitude":0.088657,"askPrice":3.945,"askSize":3000,"bidPrice":3.94,"bidSize":12600,"shortable":3,"etf":0,"ttmEps":-0.8606906677330322,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789090200000},"marketStatusCode":5,"adr":0,"listingDate":1755187200000,"exchange":"SEHK","adjPreClose":3.835,"openAndCloseTimeList":[[1789003800000,1789012800000],[1789016400000,1789027200000]],"volumeRatio":1.143126,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02591\",,,,,undefined,":{"symbol":"02591","floatShares":420285370,"roa":"-20.15%","roe":"-41.16%","lyrEps":-0.922955,"volumeRatio":1.143126,"shares":457000000,"dividePrice":0,"high":3.97,"amplitude":0.088657,"preClose":3.835,"low":3.63,"week52Low":3.435,"pbRate":"1.64","psRate":"10.05","week52High":48.36,"institutionHeld":0,"latestPrice":3.94,"committee":0.615385,"eps":-0.9229550871910676,"divideRate":0,"volume":19157931,"delay":0,"ttmEps":-0.8606906677330322,"open":3.785,"prevYearClose":30.64,"prevWeekClose":3.595,"prevMonthClose":3.635,"prevQuarterClose":7.09,"fiveDayClose":3.6,"twentyDayClose":7.075,"sixtyDayClose":8.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02591\",params:#limit:5,,,undefined,":[{"date":"2026-08-25","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787621400000,"name":null,"time":"","dateTimestamp":1787587200000,"actualEps":null},{"market":"HK","date":"2026-03-23","symbol":"02591","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774195200000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-29","symbol":"02591","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02591\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02591\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1775750400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02591\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02591","date":"2026-09-09","current":-4.573442,"percent":0.969349,"low":-137.156472,"twenty":-67.340501,"median":-48.260992,"eighty":-11.438153,"high":-4.018047,"avg":-43.664246,"sd":30.542262,"marketCap":1751902203},"quantilePoints":[{"date":"2025-08-15","current":-137.156472,"twenty":-137.156472,"median":-137.156472,"eighty":-137.156472,"marketCap":26152907730},{"date":"2025-08-22","current":-127.373977,"twenty":-129.344203,"median":-127.373977,"eighty":-126.417438,"marketCap":24211425497},{"date":"2025-08-29","current":-106.390102,"twenty":-127.373977,"median":-126.095992,"eighty":-114.007182,"marketCap":20319324643},{"date":"2025-09-05","current":-78.151342,"twenty":-127.373977,"median":-117.586994,"eighty":-99.491273,"marketCap":18939730209},{"date":"2025-09-12","current":-83.843855,"twenty":-126.417438,"median":-105.433356,"eighty":-83.374192,"marketCap":20355870191},{"date":"2025-09-19","current":-79.271387,"twenty":-126.095992,"median":-93.890147,"eighty":-81.90749,"marketCap":19232094592},{"date":"2025-09-26","current":-78.986763,"twenty":-125.916102,"median":-85.498552,"eighty":-79.429082,"marketCap":19113321562},{"date":"2025-10-03","current":-76.5387,"twenty":-122.116665,"median":-83.843855,"eighty":-78.76383,"marketCap":18565138343},{"date":"2025-10-10","current":-69.068341,"twenty":-116.871032,"median":-83.374192,"eighty":-77.810518,"marketCap":16728724560},{"date":"2025-10-17","current":-67.838616,"twenty":-109.436934,"median":-79.738352,"eighty":-74.826182,"marketCap":16418087403},{"date":"2025-10-24","current":-59.813644,"twenty":-105.816054,"median":-79.429082,"eighty":-68.576451,"marketCap":14481173363},{"date":"2025-10-31","current":-57.61442,"twenty":-103.460611,"median":-78.986763,"eighty":-66.346017,"marketCap":13969535692},{"date":"2025-11-07","current":-56.556997,"twenty":-100.097405,"median":-78.243448,"eighty":-63.14919,"marketCap":13704580470},{"date":"2025-11-14","current":-61.96171,"twenty":-95.010372,"median":-77.299283,"eighty":-61.326336,"marketCap":15056765743},{"date":"2025-11-21","current":-54.467459,"twenty":-87.179427,"median":-75.823033,"eighty":-60.1184,"marketCap":13229488347},{"date":"2025-11-28","current":-82.342484,"twenty":-85.508442,"median":-76.5387,"eighty":-60.703449,"marketCap":20072642195},{"date":"2025-12-05","current":-82.313405,"twenty":-85.248884,"median":-75.823033,"eighty":-61.326336,"marketCap":20100051356},{"date":"2025-12-12","current":-63.824496,"twenty":-84.462171,"median":-74.404407,"eighty":-61.326336,"marketCap":15614085348},{"date":"2025-12-19","current":-62.072323,"twenty":-83.725798,"median":-74.049705,"eighty":-60.286674,"marketCap":15221220708},{"date":"2025-12-24","current":-59.762449,"twenty":-83.548712,"median":-73.276127,"eighty":-59.816947,"marketCap":14700446650},{"date":"2026-01-02","current":-56.27243,"twenty":-83.409096,"median":-71.366231,"eighty":-59.572219,"marketCap":13896444596},{"date":"2026-01-09","current":-57.1291,"twenty":-82.548826,"median":-69.803372,"eighty":-58.239982,"marketCap":14143127045},{"date":"2026-01-16","current":-56.980838,"twenty":-82.319221,"median":-67.499105,"eighty":-57.682607,"marketCap":14152263432},{"date":"2026-01-23","current":-58.213825,"twenty":-82.096799,"median":-66.291021,"eighty":-57.601428,"marketCap":14444627815},{"date":"2026-01-30","current":-54.613459,"twenty":-81.934522,"median":-64.906051,"eighty":-57.510573,"marketCap":13613216600},{"date":"2026-02-06","current":-49.064319,"twenty":-80.235292,"median":-63.834,"eighty":-57.242442,"marketCap":12261031327},{"date":"2026-02-13","current":-50.165477,"twenty":-79.691019,"median":-62.941647,"eighty":-57.039695,"marketCap":12608214032},{"date":"2026-02-20","current":-50.419859,"twenty":-79.623791,"median":-62.643943,"eighty":-56.891323,"marketCap":12653895967},{"date":"2026-02-27","current":-50.052949,"twenty":-79.470699,"median":-62.017016,"eighty":-56.651056,"marketCap":12699577902},{"date":"2026-03-06","current":-43.88908,"twenty":-79.397543,"median":-60.902753,"eighty":-56.29247,"marketCap":11045891858},{"date":"2026-03-13","current":-39.965904,"twenty":-79.214462,"median":-60.292057,"eighty":-54.71959,"marketCap":10104843999},{"date":"2026-03-20","current":-39.174717,"twenty":-78.964109,"median":-59.813644,"eighty":-50.865048,"marketCap":9867297938},{"date":"2026-03-27","current":-24.701097,"twenty":-78.775514,"median":-59.491697,"eighty":-50.290678,"marketCap":9547524394},{"date":"2026-04-02","current":-24.535908,"twenty":-78.383597,"median":-58.823921,"eighty":-50.052949,"marketCap":9529251620},{"date":"2026-04-10","current":-24.978414,"twenty":-78.348547,"median":-58.584467,"eighty":-49.631191,"marketCap":9775934068},{"date":"2026-04-17","current":-23.474521,"twenty":-78.227102,"median":-58.112982,"eighty":-48.421657,"marketCap":9191205301},{"date":"2026-04-24","current":-19.658213,"twenty":-78.155492,"median":-57.844151,"eighty":-44.116877,"marketCap":7697406030},{"date":"2026-04-30","current":-16.329046,"twenty":-77.825679,"median":-57.660489,"eighty":-41.074266,"marketCap":6395470886},{"date":"2026-05-08","current":-17.822364,"twenty":-77.322024,"median":-57.626503,"eighty":-40.478309,"marketCap":5778764764},{"date":"2026-05-15","current":-17.368107,"twenty":-77.157551,"median":-57.517602,"eighty":-40.012158,"marketCap":5646287153},{"date":"2026-05-22","current":-17.112125,"twenty":-76.782452,"median":-57.446424,"eighty":-25.37304,"marketCap":5550355090},{"date":"2026-05-29","current":-15.607197,"twenty":-76.252433,"median":-57.23775,"eighty":-24.916387,"marketCap":5079831160},{"date":"2026-06-05","current":-14.014909,"twenty":-75.020932,"median":-57.073515,"eighty":-24.414835,"marketCap":4568193490},{"date":"2026-06-12","current":-11.752443,"twenty":-74.621039,"median":-56.924891,"eighty":-23.900197,"marketCap":3828146144},{"date":"2026-06-18","current":-10.549084,"twenty":-74.404407,"median":-56.73827,"eighty":-23.474521,"marketCap":3444417891},{"date":"2026-06-26","current":-9.60263,"twenty":-74.160764,"median":-56.642046,"eighty":-20.865982,"marketCap":3120076153},{"date":"2026-07-03","current":-11.351574,"twenty":-74.088566,"median":-56.533624,"eighty":-19.581214,"marketCap":3691100339},{"date":"2026-07-10","current":-11.238926,"twenty":-74.037218,"median":-56.208644,"eighty":-19.055481,"marketCap":3649986598},{"date":"2026-07-17","current":-10.540302,"twenty":-73.42668,"median":-55.144116,"eighty":-17.753872,"marketCap":3435281504},{"date":"2026-07-24","current":-10.636027,"twenty":-71.947117,"median":-53.621015,"eighty":-17.028947,"marketCap":3467258858},{"date":"2026-07-31","current":-10.1543,"twenty":-71.465685,"median":-51.153424,"eighty":-16.590446,"marketCap":3316508473},{"date":"2026-08-07","current":-10.609247,"twenty":-70.999854,"median":-50.412223,"eighty":-15.817726,"marketCap":3471827052},{"date":"2026-08-14","current":-9.215586,"twenty":-70.625283,"median":-50.222782,"eighty":-14.020929,"marketCap":3019575896},{"date":"2026-08-21","current":-5.675745,"twenty":-69.656366,"median":-50.052949,"eighty":-12.083492,"marketCap":1863822943},{"date":"2026-08-28","current":-4.445704,"twenty":-68.330506,"median":-49.617462,"eighty":-11.852702,"marketCap":1733629429},{"date":"2026-09-04","current":-4.209722,"twenty":-67.634909,"median":-49.247121,"eighty":-11.642751,"marketCap":1642265559},{"date":"2026-09-09","current":-4.483583,"twenty":-67.340501,"median":-48.260992,"eighty":-11.438153,"marketCap":1751902203}],"updateTime":1789030879357},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02591\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2639620422","title":"Innogen says Phase IIb trial shows efsubaglutide alfa cuts weight up to 10.58% in adults with obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2639620422","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639620422?lang=en_us&edition=fundamental","pubTime":"2026-05-29 21:09","pubTimestamp":1780060155,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group flagged Phase IIb ENLIGHT results for obesity drug efsubaglutide alfa for presentation at the ADA meeting on June 8, 2026.The trial met its primary endpoint, with treated participants showing meaningful weight loss versus placebo and continued reduction through the dosing period.Innogen also reported improvements in body composition and metabolic markers, with weight loss driven mainly by fat rather than muscle.Safety looked manageable, with no hypoglycemia reported and mostly mild-to-moderate gastrointestinal side effects.The data set underpins plans to advance efsubaglutide alfa into Phase III development in obesity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL5SQw8z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160792896","title":"Stock Track | INNOGEN-B Plummets 6.52% Intraday as Cornerstone Investor Lock-ups Expire","url":"https://stock-news.laohu8.com/highlight/detail?id=1160792896","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160792896?lang=en_us&edition=fundamental","pubTime":"2026-05-15 12:12","pubTimestamp":1778818329,"startTime":"0","endTime":"0","summary":"INNOGEN-B's stock price plummeted 6.52% during Friday's intraday trading session, with the decline occurring around mid-morning.The sharp drop came as cornerstone investor lock-ups expired, allowing...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168389053","title":"Hong Kong Stocks Midday Recap: Hang Seng Index Dips 0.87%, Robotics Sector Surges Against Market Trend","url":"https://stock-news.laohu8.com/highlight/detail?id=1168389053","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168389053?lang=en_us&edition=fundamental","pubTime":"2026-05-15 12:09","pubTimestamp":1778818154,"startTime":"0","endTime":"0","summary":"The Hang Seng Index fell 0.87%, dropping 229 points to 26,159 in morning trading, while the Hang Seng Tech Index declined 1.26%. Morning session turnover reached HKD 151.1 billion. Tesla's...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSImain","513600","BK4588","BK4585","02833","600699","00358","003021","603127","BK1183","02591","02432","01801","HTImain","603986","03986","600362","BK1116","00699","HSTECH","01208","HHImain","02715","HSI","002747","MCHmain","03317","06127","02692","00241","01888"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147698784","title":"Stock Track | INNOGEN-B Plummets 5.46% Intraday as Lock-Up Period Expires and Financial Losses Widen","url":"https://stock-news.laohu8.com/highlight/detail?id=1147698784","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147698784?lang=en_us&edition=fundamental","pubTime":"2026-05-14 14:19","pubTimestamp":1778739592,"startTime":"0","endTime":"0","summary":"INNOGEN-B's stock price plummeted 5.46% during intraday trading on Thursday, continuing a downward trend following a significant surge earlier in the week.The decline comes ahead of the expiration of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122129496","title":"INNOGEN-B Shares Extend Losses as Lock-Up Period Nears End","url":"https://stock-news.laohu8.com/highlight/detail?id=1122129496","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122129496?lang=en_us&edition=fundamental","pubTime":"2026-05-14 14:18","pubTimestamp":1778739501,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) saw its share price decline by over 5%, continuing a downward trend after a significant surge earlier in the week. The stock had jumped more than 32% on heavy volume this past...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","02591","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198355694","title":"INNOGEN-B Shares Plunge Over 9% Following Previous Day's Surge, Lock-Up Period for Cornerstone Investors Nears End","url":"https://stock-news.laohu8.com/highlight/detail?id=1198355694","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198355694?lang=en_us&edition=fundamental","pubTime":"2026-05-12 16:01","pubTimestamp":1778572884,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) fell more than 9% today, after closing up over 32% in the previous trading session. As of the time of writing, the stock was down 9.1% to HK$15.18, with a turnover of HK$131...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4588","BK1161","BK4585","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160489079","title":"INNOGEN-B Shares Surge Over 43% in Morning Trading; Phase III Weight Loss Data for Suba Anticipated by End-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1160489079","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160489079?lang=en_us&edition=fundamental","pubTime":"2026-05-11 11:42","pubTimestamp":1778470951,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) rose over 43% in morning trading. As of the time of writing, the stock was up 42.21%, trading at HK$17.99 with a turnover of HK$173 million. According to the company's annual...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK4588","VXUS","BK4134","BK4585","III","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129972784","title":"INNOGEN-B Shares Hit Record Low as Lock-Up Expiry Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=1129972784","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129972784?lang=en_us&edition=fundamental","pubTime":"2026-05-07 14:18","pubTimestamp":1778134696,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) fell more than 7% in afternoon trading, hitting a record low of HK$12.33. At the time of writing, the stock was down 6.16% at HK$12.49, with a turnover of HK$11.02 million. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","VXUS","BK4585","BK4588","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181023653","title":"Innogen Pharmaceutical Reports No Share Capital Changes in April 2026; Public Float Remains Compliant","url":"https://stock-news.laohu8.com/highlight/detail?id=1181023653","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181023653?lang=en_us&edition=fundamental","pubTime":"2026-05-06 11:23","pubTimestamp":1778037794,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group Co., Ltd. (Innogen Pharmaceutical) submitted its Monthly Return for Equity Issuer covering the period ended 30 April 2026. Key points are as follows: • Stable...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178804191","title":"英诺加医药2025年首度实现收入破1.31509亿元，推进糖尿病及代谢病产品全球布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1178804191","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178804191?lang=en_us&edition=fundamental","pubTime":"2026-04-28 23:07","pubTimestamp":1777388830,"startTime":"0","endTime":"0","summary":"2025年度，英诺加医药集团有限公司（股份代号：02591，简称“INNOGEN-B”）实现自成立以来的首次营收，报告期内收入约人民币1.31509亿元，主要来自集团核心长效GLP-1受体激动剂Efsugablutide...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英诺加医药2025年首度实现收入破1.31509亿元，推进糖尿病及代谢病产品全球布局","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630863075","title":"Guangzhou Innogen Pharma publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2630863075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630863075?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:53","pubTimestamp":1777387985,"startTime":"0","endTime":"0","summary":"Innogen Pharma annual report for year ended Dec. 31, 2025 flagged a strategic shift toward commercial execution following launch of core GLP-1 product Diabegone  in mainland China in February 2025.Product reached a reimbursement milestone in December 2025 with inclusion in China National Reimbursement Drug List for adult type 2 diabetes, effective Jan. 1, 2026.Group recorded first year of scalable product sales with revenue of RMB 131.51 million, reflecting initial market penetration in China.Pipeline advanced in weight management with Phase III China obesity and overweight study completing enrollment in November 2025, with completion targeted in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangzhou Innogen Pharmaceutical Grou","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL3jCf9s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100842642","title":"Domestic Long-Acting GLP-1 Drug Tops 100 Million Yuan in First-Year Sales but Faces Deepening Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=1100842642","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100842642?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:12","pubTimestamp":1777018368,"startTime":"0","endTime":"0","summary":"INNOGEN-B has become the first domestic company to commercialize a long-acting GLP-1 drug following the approval of its Esupaglutide α injection in 2025. One year later, the company released its...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161","GLP","BK4144","BK4590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127480276","title":"INNOGEN-B (02591): 2025 Losses Nearly Double Amid Strategic Transition, Share Price Plummets Over 70%","url":"https://stock-news.laohu8.com/highlight/detail?id=1127480276","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127480276?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:18","pubTimestamp":1775477936,"startTime":"0","endTime":"0","summary":"The year 2025 marked a pivotal period of strategic transformation for INNOGEN-B (02591), as the company shifted from a pure research and development focus to a dual approach integrating R&D with...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147586009","title":"INNOGEN-B Shares Climb Over 3% in Morning Session as Esupaglutide Alpha Added to Qilu Insurance List","url":"https://stock-news.laohu8.com/highlight/detail?id=1147586009","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147586009?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:38","pubTimestamp":1775093921,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) rose more than 3% during morning trading. At the time of writing, the stock was up 2.94% to HK$22.22, with a turnover of HK$1.966 million. On April 1, INNOGEN announced via its...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","02591","BK4585","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621321340","title":"Innogen Pharmaceutical's 2025 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2621321340","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621321340?lang=en_us&edition=fundamental","pubTime":"2026-03-24 11:11","pubTimestamp":1774321897,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical  booked 341.4 million yuan in attributable loss for 2025, widening from a loss of 174.7 million yuan in  2024, according to a Hong Kong bourse filing Monday.Loss per share was 0.79 yuan, compared with 0.42 yuan in the prior year.Revenue for the year was 131.5 million yuan. The company did not generate any revenue in 2024.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188306372","title":"Stock Track | INNOGEN-B Plummets 5.79% Intraday as FY2025 Loss Widens 95.4% on Surging R&D and Commercial Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=1188306372","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188306372?lang=en_us&edition=fundamental","pubTime":"2026-03-24 09:42","pubTimestamp":1774316538,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) shares plummeted 5.79% during Tuesday's intraday trading session, following the release of the company's first post-IPO annual results for the fiscal year 2025.The pharmaceutical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621070763","title":"BRIEF-Guangzhou Innogen Pharmaceutical Posts FY Revenue Rmb131.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621070763","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621070763?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:18","pubTimestamp":1774279127,"startTime":"0","endTime":"0","summary":"BRIEF-Guangzhou Innogen Pharmaceutical Posts FY Revenue Rmb131.5 MillionMarch 23  - Guangzhou Innogen Pharmaceutical 2591.HK:FY REVENUE RMB131.5 MILLIONFY LOSS ATTRIBUTABLE RMB341.4 MILLIONPLANS TO ENTER THE LATIN AMERICA MARKETFurther company coverage: 2591.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0AT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103158318","title":"INNOGEN-B Reports Widened Net Loss of 341 Million Yuan for Fiscal Year 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1103158318","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103158318?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:16","pubTimestamp":1774278975,"startTime":"0","endTime":"0","summary":"INNOGEN-B (02591) announced its financial results for the year ended December 31, 2025. The group reported revenue of approximately 131.5 million yuan, primarily generated from the sales of...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190961010","title":"Innogen Pharmaceutical posts 2025 maiden revenue of RMB131.51 million; net loss widens on surging R&D and commercial spend","url":"https://stock-news.laohu8.com/highlight/detail?id=1190961010","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190961010?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:02","pubTimestamp":1774278135,"startTime":"0","endTime":"0","summary":"Guangzhou Innogen Pharmaceutical Group (Innogen-B) released its first post-IPO annual results, highlighting the transition from pure R&D to simultaneous development and commercialisation. Revenue and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621870210","title":"Guangzhou Innogen Pharmaceutical - Plans to Enter the Latin America Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2621870210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621870210?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277747,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0AT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02591","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":116,"code":"91000000","status":"200"}]}}